Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of MDS!
Quiz|Articles|October 11, 2026 (Updated: June 1, 2026)
NeurologyLive® Brain Games: October 11, 2026
Author(s)Louie Pasculli
Listen
0:00 / 0:00
Key Takeaways
- Weekly cadence delivers three questions curated by neurologists and clinicians, emphasizing both bedside knowledge and historical context.
- Topic coverage ranges from neurodegeneration and epilepsy to migraine, movement disorders, MS, neuromuscular and sleep medicine, and cerebrovascular disease.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of recent therapeutic advances in MS!
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
In May 2026, the FDA expanded the indication for intravenous ocrelizumab (Ocrevus) to include pediatric patients with relapsing-remitting multiple sclerosis. Which patient best meets the newly approved population?
In the phase 3 pediatric study supporting the 2026 FDA approval of ocrelizumab for RRMS, which interpretation of the primary efficacy result is most accurate?
A 16-year-old patient with RRMS is being considered for ocrelizumab following the 2026 pediatric FDA approval. Which statement most accurately distinguishes this approval from the earlier adult approval?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.
Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of communication between patients and their health care teams, including navigating medical language, promoting shared decision-making, and advocating for clear, patient-centered care.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease
2
CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease
3
Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient
4
Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches
5